N/A
Completed N=72
Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine
Nasolabial Folds
Source: ClinicalTrials.gov NCT00653861 ↗
Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Dec 2009
Primary outcomePrimary: Procedural Pain Score — 2.0; 5.4 Units on a scale
Summary
Safety and effectiveness of JUVÉDERM™ Injectable Gel with Lidocaine compared to JUVÉDERM™ without Lidocaine for procedural pain in the treatment of nasolabial folds.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Procedural Pain Score |
2.0; 5.4 | — |
| SECONDARY Comparative Pain |
64; 29; 0; 4; 3 | — |
| SECONDARY Nasolabial Fold (NLF) Severity |
1.6; 1.6; 1.8; 1.8 | — |
Eligibility Criteria
Inclusion Criteria
- Be male or female, 18 years of age or older
- Desire correction of moderate to severe nasolabial folds (NLFs)
- Have approximately symmetrical NLFs, i.e., both NLFs have the same pretreatment NLF severity score
Exclusion Criteria
- Have undergone cosmetic facial procedures in the lower 2/3 of the face within 1 month prior to entry in the study or are planning to undergo these procedure during the study.
- Begin use of any new over-the-counter or prescription, oral or topical, anti-wrinkle products in the NLF area within 1 month prior to enrollment or are planning to begin use of such products during the study.
- Have undergone previous hyaluronic acid (HA)-based dermal filler treatments such that the total volume of HA injected within 12 months prior to study entry is within 5 mL of the recommended annual maximum volume for HA dermal fillers.
- Has ever received semi-permanent fillers or permanent facial implants anywhere in the face or neck, or is planning to be implanted with these products during the study.
- Have a history of anaphylaxis, multiple severe allergies, atopy, or allergy to lidocaine (or any amide-based anesthetic), hyaluronic acid products, or Streptococcal protein, or have plans to undergo desensitization therapy during the term of the study.
- Have an active inflammation, infection, cancerous or pre-cancerous lesion, or unhealed wound in the NLF area
Data sourced from ClinicalTrials.gov (NCT00653861). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.